United States Government Publishing Office publisher pbl distributor dst United States National Archives and Records Administration Office of the Federal Register author aut Government Organization text government publication eng FR Regulatory Information 2024_register executive 2024-08-13 article Notices D09002ee1ca551449 D09002ee1ca551597 United States Department of Health and Human Services originator org United States Government Agency or Subagency United States Food and Drug Administration originator org United States Government Agency or Subagency The Food and Drug Administration (FDA or the Agency) is announcing the renewal of the Peripheral and Central Nervous System Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Peripheral and Central Nervous System Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the June 4, 2026, expiration date. 89 FR 65916 https://www.govinfo.gov/app/details/FR-2024-08-13/2024-18004 2024-18004 fr13au24-46 4164-01-P Docket No. FDA-2022-N-0691 https://www.govinfo.gov/app/details/FR-2024-08-13/2024-18004 https://www.govinfo.gov/content/pkg/FR-2024-08-13/html/2024-18004.htm https://www.govinfo.gov/content/pkg/FR-2024-08-13/pdf/2024-18004.pdf 2 p. 65916 65917 89 FR 65916 Advisory Committee; Peripheral and Central Nervous System Drugs Advisory Committee; Renewal; Federal Register Vol. 89, Issue NOTICE 2024-18004 DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Docket No. FDA-2022-N-0691 4164-01-P 2024-18004 Notice; renewal of Federal advisory committee.

The Food and Drug Administration (FDA or the Agency) is announcing the renewal of the Peripheral and Central Nervous System Drugs Advisory Committee by the Commissioner of Food and Drugs (the Commissioner). The Commissioner has determined that it is in the public interest to renew the Peripheral and Central Nervous System Drugs Advisory Committee for an additional 2 years beyond the charter expiration date. The new charter will be in effect until the June 4, 2026, expiration date.

Authority for the Peripheral and Central Nervous System Drugs Advisory Committee will expire on June 4, 2026, unless the Commissioner formally determines that renewal is in the public interest. Jessica Seo, Center for Drug Evaluation Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-796-9001, PCNS@fda.hhs.gov. Charter Amendments, Establishments, Renewals and Terminations: Peripheral and Central Nervous System Drugs Advisory Committee, PCNS@fda.hhs.gov http://www.fda.gov/AdvisoryCommittees/default.htm https://www.fda.gov/advisory-committees/human-drug-advisory-committees/Peripheral-and-Central-Nervous-System-Drugs-advisory-committee Vol. 89, no. 156 Office of the Federal Register, National Archives and Records Administration 2024-08-13 continuing daily deposited born digital 243 p. Table of Contents: AE 2.7: GS 4.107: AE 2.106: KF70.A2 https://www.govinfo.gov/app/details/FR-2024-08-13 P0b002ee1ca53c57d 0097-6326 0042-1219 0364-1406 769-004-00000-9 000582072 f:fr13au24 https://www.govinfo.gov/app/details/FR-2024-08-13 https://www.govinfo.gov/content/pkg/FR-2024-08-13/pdf/FR-2024-08-13.pdf https://www.govinfo.gov/content/pkg/FR-2024-08-13/xml/FR-2024-08-13.xml fdlp 65755 65987 DGPO 2024-08-13 2024-08-13 FR-2024-08-13 machine generated eng FR FR-2024-08-13 89 156